Serum levels of CXCL13 are elevated in active multiple sclerosis

Abstract

There is increasing recognition of the important role that B cells play in the pathogenesis of multiple sclerosis (MS). Recently it was reported that the B cell chemokine CXCL13 is elevated in MS serum and cerebrospinal fluid. Here we study whether serum levels of CXCL13 are associated with active MS. We measured serum levels of CXCL13 by enzyme-linked immunosorbent assay in 74 patients with relapsing MS randomized to interferon beta 1b or glatiramer acetate and examined with monthly 3 T brain MRI scans optimized for detection of gadolinium-enhancement for up to 2 years. The median (range) serum levels of CXCL13 pre-treatment were 40 (3—171) pg/ml. Serum levels of CXCL13 were significantly higher at times of active brain MRI scans (p < 0.01). Furthermore, serum levels were higher in patients who never reached MRI remission compared with those in complete (p < 0.01) or partial (p = 0.01) remission. There was a significant positive correlation between the pattern of serum levels of CXCL13 and MRI activity during the first (r = 0.33, p < 0.05) and the full 2 years (r = 0.35, p < 0.01) of the study. Treatment with interferon beta 1b or glatiramer acetate did not affect serum CXCL13. We conclude that the serum levels of the B cell chemokine CXCL13 are associated with active MS.

Keywords

multiple sclerosis brain MRI CXCL13 biomarkers

Get full access to this article

View all access options for this article.

References

Miller DH , Rudge P. , Johnson G. , et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-39.

McFarland HF , Frank JA , Albert PS , et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis . Ann Neurol 1992; 32: 758-66.

Cadavid D. , Wolansky LJ , Skurnick J. , et al. Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009; 72: 1976-83.

Lucchinetti CF , Gavrilova RH , Metz I. , et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131: 1759-75.

Ransohoff RM , Liu L. , Cardona AE Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol 2007; 82: 187-204.

Krumbholz M. , Theil D. , Cepok M. , et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 Up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129: 200-11.

Michalowska- Wender G. , Losy J. , Blernacka-Lukanty J. , Wender M. Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients. Pharmacol Rep 2008; 60: 549-54.

Gunn MD , Ngo VN , Ansel KM , et al. A B-cell-homing chemokine made in lymphoid follicles activates burkitt’s lymphoma receptor-1. Nature 1998; 391: 799-803.

Hauser SL , Waubant E. , Arnold DL , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88.

10.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.

11.

Rudick RA , Cutter G. , Baier M. , et al. Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology 2001 ; 56: 1324-30.

12.

Kantor AB , Deng J. , Waubant E. , et al. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad-based phenotypic profiling. J Neuroimmunol 2007; 188: 103-16.

13.

Kalkers NF , Bergers L. , de Groot V. , et al. Concurrent validity of the ms functional composite using MRI as a biological disease marker. Neurology 2001; 56: 215-9.

14.

Widney DP , Breen EC , Boscardin WJ , et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res 2005; 25: 702-6.

15.

Burkle A. , Niedermeier M. , Schmitt-Graff A. , et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007; 110: 3316-25.

16.

Rioja I. , Hughes FJ , Sharp CH , et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008; 58: 2257-67.

17.

Londono D. , Marques A. , Hornung RL , Cadavid D. , et al. Relapsing fever borreliosis in IL-10 deficient mice. Infect Immun 2008; 76: 5508-13.

18.

Gelderblom H. , Londono D. , Bai Y. , et al. High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete borrelia turicatae. J Neuropathol Exp Neurol 2007; 66: 208-17.

19.

Cadavid D. The mammalian host response to borrelia infection. Wien Klin Wochenschr 2006; 118: 653-8.

20.

Narayan K. , Dali D. , Li L. , et al. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol 2005; 57: 813-23.

21.

Pachner AR , Dail D. , Narayan K. , Dutta K. , Cadavid D. , et al. Increased expression of B-lymphocyte chemoattractant, but not pro-inflammatory cytokines, in muscle tissue in rhesus chronic lyme borreliosis . Cytokine 2002; 19: 297-307.

22.

Magliozzi R. , Columba-Cabezas S. , Serafini B. , Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 11-23.

23.

Ljostad U. , Mygland A. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute lyme neuroborreliosis. J Neurol 2008; 255: 732-7.

24.

Rupprecht TA , Pfister HW , Angele B. , et al. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 2005; 65: 448-50.

25.

Columba-Cabezas S. , Griguoli M. , Rosicarelli B. , et al. Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin Beta Receptor-Ig fusion protein. J Neuroimmunol 2006; 179: 76-86.

26.

Ukkonen M. , Wu K. , Reipert B. , Dastidar P. , Elovaara I. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Mult Scler 2007; 13: 701-7.

27.

Bartosik-Psujek H. , Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005; 12: 49-54.

28.

Losy J. , Michalowska-Wender G. , Kurdynska A. , Wender M. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with glatiramer acetate (Copaxone). Folia Neuropathol 2005; 43: 153-5.